Bionomics Limited, (BNOX): Price and Financial Metrics

Bionomics Limited, (BNOX): $0.84

0.01 (+1.31%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add BNOX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#176 of 362

in industry

BNOX Price/Volume Stats

Current price $0.84 52-week high $6.41
Prev. close $0.83 52-week low $0.65
Day low $0.75 Volume 1,420,400
Day high $0.86 Avg. volume 351,255
50-day MA $0.82 Dividend yield N/A
200-day MA $1.40 Market Cap 6.86M

BNOX Stock Price Chart Interactive Chart >


Bionomics Limited, (BNOX) Company Bio


Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.


BNOX Latest News Stream


Event/Time News Detail
Loading, please wait...

BNOX Latest Social Stream


Loading social stream, please wait...

View Full BNOX Social Stream

Latest BNOX News From Around the Web

Below are the latest news stories about BIONOMICS LIMITED that investors may wish to consider to help them evaluate BNOX as an investment opportunity.

Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals

After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.

Yahoo | December 22, 2023

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

A psychometric analysis concluded that Subjective Units of Distress Scale (SUDS) is a psychometrically valid, sensitive, and reliable tool for evaluation of social anxiety.SUDS will be used as the primary outcome in future Phase 3 social anxiety disorder (SAD) clinical trials. ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion c

Yahoo | December 6, 2023

12 Best Stocks For Day Trading

In this piece, we will take a look at the 12 Best Stocks For Day Trading. If you want to skip our introduction to trading indicators and the economic climate, then check out 5 Best Stocks For Day Trading. The modern day stock market is significantly different from the one of the early 1900s. These […]

Yahoo | October 30, 2023

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

Positive outcome of End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) in September 2023 enables advancement of BNC210 into Phase 3 studies in Social Anxiety DisorderCompany confirms agreement with the FDA on Phase 3 clinical program and alignment on nonclinical toxicology studies required for registrationCompany is on track for first patient dosed in the Phase 3 program planed for Q1’24 ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bionomics Limit

Yahoo | October 16, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning!

William White on InvestorPlace | October 2, 2023

Read More 'BNOX' Stories Here

BNOX Price Returns

1-mo 9.37%
3-mo -14.23%
6-mo -19.23%
1-year -67.23%
3-year N/A
5-year N/A
YTD -43.24%
2023 -68.17%
2022 -62.95%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!